Mergers, Acquisitions and Takeovers Case Study

Novartis' Acquisition of Aventis : The Potential Synergies

OR

Abstract:
After Aventis rejected the hostile takeover bid of Sanofi-Synthelabo on the grounds of financial inadequacy in January 2004, it approached Novartis, the Swiss drug manufacturer, to acquire it and save it from the potential acquisition. Although the Novartis-Aventis combination had the potential to form the second largest pharmaceutical company in the world with combined revenues of $47 billion, the French government was against the takeover of Aventis by a foreign company.

Pedagogical Objectives:

• To discuss the probable synergies in case Aventis is acquired by Novartis.

Keywords : Ciba-Geigy;Mergers, Acquisitions, Alliances Case Study; Sandoz; Global pharmaceutical companies; Mergers and acquisitions; Sanofi-Synthelabo; Aventis; Novartis AG; Hostile takeovers; Hoechst AG; Prescription drugs; Rhone-Poulenc SA; Pfizer; Merk & Company; Anti-diabetic drugs; Anti-cancerous drugs

Contents : 
A Briefoverviewof The Companies
The Probable Synergies
A Challengingfuture
Mergers And Acquisitions In The Global Pharmaceutical Industry
Bad Chemistry
Sales Of The Ten Best Selling Drugs Of Novartis
Aventis And Novartis: Product Classification Accordin